# Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma

> **NCT03746223** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Primary Intraocular Lymphoma

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Rituximab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT03746223
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-15
- **Primary completion:** 2020-11-15
- **Final completion:** 2025-10-15
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2019-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03746223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03746223, "Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03746223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*